Hyperalgesia - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 36 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hyperalgesia - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Hyperalgesia - Pipeline Review, H2 2016', provides an overview of the Hyperalgesia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Hyperalgesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperalgesia
- The report reviews pipeline therapeutics for Hyperalgesia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hyperalgesia therapeutics and enlists all their major and minor projects
- The report assesses Hyperalgesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hyperalgesia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hyperalgesia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hyperalgesia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hyperalgesia Overview 6
Therapeutics Development 7
Pipeline Products for Hyperalgesia - Overview 7
Pipeline Products for Hyperalgesia - Comparative Analysis 8
Hyperalgesia - Therapeutics under Development by Companies 9
Hyperalgesia - Therapeutics under Investigation by Universities/Institutes 10
Hyperalgesia - Pipeline Products Glance 11
Early Stage Products 11
Hyperalgesia - Products under Development by Companies 12
Hyperalgesia - Products under Investigation by Universities/Institutes 13
Hyperalgesia - Companies Involved in Therapeutics Development 14
Boehringer Ingelheim GmbH 14
Cara Therapeutics, Inc. 15
Shionogi & Co., Ltd. 16
Hyperalgesia - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
AX-007 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
BAM-822 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
BI-113823 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
CR-701 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
GERP-001 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
ketoprofen - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
LASSBio-873 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecule to Antagonize P2X3 Receptor for Hyperalgesia - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Hyperalgesia - Dormant Projects 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 35
Disclaimer 36

List of Tables

Number of Products under Development for Hyperalgesia, H2 2016 7
Number of Products under Development for Hyperalgesia - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Products under Investigation by Universities/Institutes, H2 2016 13
Hyperalgesia - Pipeline by Boehringer Ingelheim GmbH, H2 2016 14
Hyperalgesia - Pipeline by Cara Therapeutics, Inc., H2 2016 15
Hyperalgesia - Pipeline by Shionogi & Co., Ltd., H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Stage and Target, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Hyperalgesia - Dormant Projects, H2 2016 34